OCGN · Ocugen, Inc.

Ocugen’s issuance of $115.0 million in convertible senior notes represents a pivotal capital structure event, replacing secured debt with unsecured, convertible obligations that defer equity dilution while introducing significant near-term interest expense and complex conversion mechanics. The $32.7 million repayment of the Avenue Loan Agreement eliminates a secured facility with potentially restrictive covenants, improving financial flexibility but increasing reliance on unsecured credit. The 6.75% coupon is materially higher than typical investment-grade rates, reflecting Ocugen’s speculative credit profile and the notes’ subordination to secured debt. The 45% conversion premium signals management’s confidence in future stock performance, yet the Nasdaq Exchange Cap—capping physical settlement at ~67.6 million shares—creates a hard constraint on dilution until stockholder approval is obtained, which introduces execution risk and potential governance friction. The as-adjusted $99.0 million cash balance as of March 31, 2026, provides runway but remains subject to the Company’s clinical development timeline and burn rate; no forward guidance on cash use or operational milestones is disclosed. Critically, the notes contain multiple investor protections—including put rights at maturity (2032) and upon fundamental change—as well as stringent cross-default provisions tied to other indebtedness exceeding $10.0 million, meaning any future financing stress could trigger immediate repayment obligations. The absence of GAAP earnings data or revenue disclosures in this filing limits assessment of underlying operating health, making the financing terms themselves the primary signal of financial condition and strategic posture.